What ESTEVE does

ESTEVE is a privately held Spanish specialty pharmaceutical company headquartered in Barcelona that operates a dual-engine business model combining proprietary pharmaceutical products with contract development and manufacturing (CDMO) services. The company employs between 1,001 and 5,000 people and reported €828 million in 2025 net revenue (+14% YoY) alongside €151 million in EBITDA (+19% YoY) at an 18% margin, with management targeting €1 billion in revenue by 2027.

On the pharmaceutical side, ESTEVE commercializes specialty medications across rare diseases (Cushing's syndrome, adrenocortical carcinoma via the HRA Pharma Rare Diseases portfolio acquired from Perrigo in 2024), infusion therapies (Prialt for severe chronic pain and Quzyttir for acute urticaria, consolidated globally via the March 2026 TerSera acquisition), and supportive cancer care (AKYNZEO and ALOXI for chemotherapy-induced nausea and vomiting, distributed in DACH markets under a 15-year partnership with Helsinn Healthcare). The company sells these products through a direct enterprise sales force covering seven European markets — Spain, France, Germany, Italy, Portugal, the UK, and Benelux — and is now expanding into the United States following the TerSera acquisition.

On the CDMO side, ESTEVE CDMO is a global pure-play contract development and manufacturing organization specializing in high-quality small-molecule active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and high-potency APIs (HP APIs) used in oncology and hormonal therapies. Capabilities were significantly expanded through the July 2025 acquisition of U.S.-based Regis Technologies and a $15.5 million investment in the Morton Grove, Illinois facility announced in March 2026, alongside the addition of spray dryers and containment capabilities at the Celrà, Girona, Spain site. The company has cumulatively deployed approximately €500 million in inorganic investments over two years, is partially owned (26% stake) by German private investment firm Lubea since May 2023, and achieved B Corp Certification in January 2026.

Name

ESTEVE

Legal name

ESTEVE

Website

https://esteve.es

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ESTEVE is a Barcelona-based private specialty pharmaceutical company operating a dual-engine model: proprietary drugs in rare diseases, infusion therapies, and supportive cancer care, plus a global CDMO business specializing in small-molecule APIs and high-potency APIs. It serves healthcare providers across Europe and is expanding into the U.S.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Specialty pharmaceuticals
• Contract manufacturing
• Active pharmaceutical ingredients
• Rare disease treatments
• Infusion therapies

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations

Revenue model

1. Pharmaceutical Products: ESTEVE develops and commercializes proprietary pharmaceutical products across specialty therapeutic areas including rare diseases (Cushing's syndrome, adrenocortical carcinoma), infusion therapies (Prialt for severe chronic pain, Quzyttir for acute urticaria), and supportive cancer care (AKYNZEO, ALOXI for chemotherapy-induced nausea and vomiting). Revenue is generated through product sales in global markets, with strong European presence and expanding U.S. footprint following acquisitions.
2. CDMO Services (Contract Development and Manufacturing): ESTEVE CDMO provides contract development and manufacturing services for small-molecule APIs and pharmaceutical intermediates to pharmaceutical companies globally. Revenue is generated through service contracts and manufacturing fees. The business is expanding with new facilities in the USA and Spain, adding early development capabilities and spray drying capacity.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

ESTEVE operates a dual-engine business combining proprietary specialty pharmaceuticals (rare disease treatments, infusion therapies, and supportive cancer care products such as Prialt, Quzyttir, AKYNZEO, and ALOXI) with a pure-play contract development and manufacturing (CDMO) organization specializing in small-molecule active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and high-potency APIs (HP APIs) for pharmaceutical companies globally.

Product overview

ESTEVE is a specialty pharmaceutical company operating two core business units: Pharma and CDMO Services. The Pharma business encompasses a portfolio of specialty medications including rare disease treatments (HRA Pharma Rare Diseases), severe chronic pain therapy (Prialt®), acute urticaria treatment (Quzyttir®), and supportive cancer care products (AKYNZEO®, ALOXI®). The CDMO Services business is a pure-play contract development and manufacturing organization specializing in small-molecule APIs and pharmaceutical intermediates, with capabilities including HPAPI manufacturing, spray drying, containment, and expansion into biologics. The company has grown through aggressive inorganic acquisition, integrating eight new products over 18 months and expanding CDMO capacity through facilities in Spain, China, and the United States.

Differentiator

Problem solved

Functional benefit

Brands

• ESTEVE CDMO: Global contract development and manufacturing organization specializing in high-quality small-molecule APIs and pharmaceutical intermediates

Products and services

• ESTEVE Pharma Specialty pharmaceutical business focused on therapeutic solutions in rare diseases, severe chronic pain, and supportive cancer care. Portfolio includes both internally developed and acquired brands marketed across Europe and the United States.
• ESTEVE CDMO Global contract development and manufacturing organization (CDMO) offering services including early development, spray drying, containment capabilities, and HPAPI manufacturing for pharmaceutical company clients globally. Facilities in Spain, the United States, and China.
• HRA Pharma Rare Diseases Portfolio

Quantifiable outcome

• Net revenue of €828 million in 2025 (+14% YoY)
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Helsinn Healthcare SAcoreChannel Partner/ Reseller/ Distributor · 9 February 2026ESTEVE and Helsinn expanded their partnership by extending their Distribution and Licence Agreement for AKYNZEO and ALOXI to Austria. The two companies have collaborated for over 15 years with previous agreements covering Germany, strengthening their presence in the German-speaking region for supportive cancer care treatments.
• TerSera TherapeuticscoreStrategic or Co-development Partner · 13 January 2026ESTEVE acquired TerSera Therapeutics' Infusion Specialty Therapies Business Unit, gaining worldwide rights (excluding China) to Quzyttir and consolidating global rights for Prialt. The deal closed in Q1 2026 and marked ESTEVE's strategic expansion into the U.S. pharmaceutical market.
• Regis Technologies Inc.coreStrategic or Co-development Partner · 1 July 2025In July 2025, ESTEVE acquired U.S.-based Regis Technologies Inc., a CDMO specializing in high-potency APIs. The acquisition was aimed at bolstering ESTEVE's U.S. footprint and manufacturing capabilities in the HP API space.
• Perrigo Company plccoreStrategic or Co-development Partner · 10 July 2024ESTEVE completed the acquisition of HRA Pharma Rare Diseases from Perrigo for up to €275 million (€190M upfront + earnouts). The acquisition expanded ESTEVE's rare disease portfolio including treatments for Cushing's syndrome and adrenocortical carcinoma, accelerating its international growth.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: Swiss-headquartered global CDMO leader operating across small molecules, biologics, and cell/gene therapy manufacturing. Competes with ESTEVE CDMO in API manufacturing with significantly larger scale and broader service portfolio.
• Catalent: Global CDMO leader (now owned by Novo Holdings) with broad capabilities across small molecules, biologics, and cell/gene therapies. Larger incumbent competing with ESTEVE CDMO in small-molecule API manufacturing with significantly broader scale and geographic reach.
• Chiesi Farmaceutici: Italian specialty pharmaceutical company with focus on rare diseases, respiratory, and specialty therapeutics with global commercial presence. Comparable to ESTEVE's specialty pharma arm as a larger European specialty pharma with established rare disease capabilities.
• Recordati: Italian specialty pharmaceutical company with focus on rare diseases and specialty therapeutics across global markets. Comparable to ESTEVE's specialty pharma arm as a larger European specialty pharma competitor in rare disease and specialty therapeutic areas.

Emerging players

• Helsinn Healthcare: Swiss specialty pharmaceutical company focused on supportive cancer care (including AKYNZEO and ALOXI that ESTEVE distributes in Europe). Comparable to ESTEVE's supportive cancer care segment and serves as both partner and adjacent specialty pharma peer.

Direct peers

• Almirall: Spanish specialty pharmaceutical company focused on dermatology and rare diseases with established European commercial footprint. Comparable to ESTEVE's specialty pharma arm, particularly its rare disease portfolio acquired through HRA Pharma.
• Faes Farma: Spanish specialty pharmaceutical company with focus on prescription pharma, OTC, and animal health across European markets. Comparable to ESTEVE's specialty pharma segment as a similarly-sized Spanish player pursuing growth through specialty therapeutic areas.
• Cambrex: US-based CDMO specializing in small-molecule APIs and finished dosage forms with HP API capabilities. Direct competitor to ESTEVE CDMO in the high-potency API manufacturing space, particularly relevant given ESTEVE's US expansion through Regis Technologies acquisition.
• Laboratorios Farmaceuticos Rovi: Spanish specialty pharmaceutical company operating both proprietary pharma and CDMO services, with a similar dual-engine model serving European and select international markets. Closest comparable to ESTEVE given shared Spanish heritage, specialty pharma focus, and contract manufacturing capabilities.
• Recipharm: European CDMO specializing in small-molecule APIs and finished dosage forms with facilities across Europe. Direct competitor to ESTEVE CDMO in the contract manufacturing of small-molecule APIs and pharmaceutical intermediates for global pharmaceutical clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/esteve
• Instagraminstagram.com/esteve
• Xx.com/esteve_news

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ESTEVE